<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H452C02E2656D4E6E80A9138B63C9F36F" public-private="public">
	<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>112th CONGRESS</congress>
		<session>2d Session</session>
		<legis-num>H. R. 4056</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20120216">February 16, 2012</action-date>
			<action-desc><sponsor name-id="B000461">Mr. Bilbray</sponsor> (for
			 himself, <cosponsor name-id="D000598">Mrs. Davis of California</cosponsor>,
			 <cosponsor name-id="L000274">Mr. Lewis of California</cosponsor>,
			 <cosponsor name-id="R000487">Mr. Royce</cosponsor>,
			 <cosponsor name-id="C000059">Mr. Calvert</cosponsor>,
			 <cosponsor name-id="B001228">Mrs. Bono Mack</cosponsor>, and
			 <cosponsor name-id="H001048">Mr. Hunter</cosponsor>) introduced the following
			 bill; which was referred to the <committee-name committee-id="HIF00">Committee
			 on Energy and Commerce</committee-name></action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To amend the Federal Food, Drug, and Cosmetic Act to
		  prevent a State or political subdivision thereof from conducting or requiring
		  duplicative inspections of establishments in which a drug or device is
		  manufactured, processed, packed, or held by a manufacturer or wholesale
		  distributor of the drug or device.</official-title>
	</form>
	<legis-body id="H8C4638D6A4DD44F396F8B216DD5C27CA" style="OLC">
		<section id="H1266A52611C04B39BB3F4819C938FAA4" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the
			 <quote><short-title>Science and Technology Regulatory Relief Act of
			 2012</short-title></quote>.</text>
		</section><section id="H5AB2DDF7DCD94732AF49D3640A809C40"><enum>2.</enum><header>Limitation of
			 State authority To inspect</header><text display-inline="no-display-inline">Section 704 of the Federal Food, Drug, and
			 Cosmetic Act (21 U.S.C. 374) is amended by adding at the end the
			 following:</text>
			<quoted-block display-inline="no-display-inline" id="H0CE21892139E4C9A89D0586D0755CF58" style="OLC">
				<subsection id="H2AA4B91961FB45C09AAC323ABD5E68E2"><enum>(h)</enum><header>Limitation of
				State authority To inspect</header>
					<paragraph id="H10FD6234744C450C8AB41CBF1F0F985F"><enum>(1)</enum><header>In
				general</header><text display-inline="yes-display-inline">Except as provided in
				paragraph (2), no State or political subdivision of a State may conduct or
				require an inspection of a factory, warehouse, or establishment in which a drug
				or device is manufactured, processed, packed, or held by a manufacturer or
				wholesale distributor of the drug or device, for introduction into interstate
				commerce or after such introduction, for purposes of verifying compliance
				with—</text>
						<subparagraph id="HB8566870E97F4D3E820565DA1A836F7E"><enum>(A)</enum><text>the requirements
				of—</text>
							<clause id="HDD3B4CB02C5F4D0A9D13A8FB7B8FA916"><enum>(i)</enum><text>section 351 of the
				Public Health Service Act; or</text>
							</clause><clause id="H28C367EA51964355AC1D46B83264739D"><enum>(ii)</enum><text>this Act;
				or</text>
							</clause></subparagraph><subparagraph id="H310CBD402306422F919DA2CE19555BC2"><enum>(B)</enum><text>any similar
				requirements established pursuant to State law.</text>
						</subparagraph></paragraph><paragraph id="HC6718CD87D8C43DBB39D49B4D6BE0664"><enum>(2)</enum><header>Exceptions</header><text>Paragraph
				(1) does not apply to an inspection of such a factory, warehouse, or
				establishment by a State or a political subdivision of a State in any of the
				following circumstances:</text>
						<subparagraph id="H9F43C6EB5DF0499995C0E331CB77F2E7"><enum>(A)</enum><text>The State or
				political subdivision (or a department or agency thereof) makes a
				determination, based on receipt of a complaint or otherwise, that a drug or
				device presents a threat of serious adverse health consequences or death, and
				the inspection relates to such risk.</text>
						</subparagraph><subparagraph id="H1B5FC3BA019A44E7B9E3A82C1449A75F"><enum>(B)</enum><text>The Secretary
				orders a recall of a drug, biological product, or device manufactured,
				processed, packed, or held at the factory, warehouse, or establishment, and the
				inspection relates to such recall.</text>
						</subparagraph><subparagraph id="H6DB25645C1E1467D8E2823887666A6AE"><enum>(C)</enum><text>The Secretary
				requests or authorizes the State to conduct or require the
				inspection.</text>
						</subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
		</section></legis-body>
</bill>
